Brief: Sio Gene Therapies Inc - Plans To Explore And Review A Range Of Strategic Alternatives

Sio Gene Therapies

27/04/2022 22:55

Sio Gene Therapies Inc  SIOX.O :
    * SIO GENE THERAPIES PROVIDES CORPORATE UPDATE
    * SIO GENE THERAPIES INC - ANNOUNCES TERMINATION OF
LICENSING
AGREEMENT FOR GM1 AND GM2 GENE THERAPIES WITH UNIVERSITY OF
MASSACHUSETTS
    * SIO GENE THERAPIES INC - PLANS TO EXPLORE AND REVIEW A
RANGE OF
STRATEGIC ALTERNATIVES
    * SIO GENE THERAPIES INC - COMPANY WILL EXPLORE OPTIONS SUCH
AS
POTENTIAL FOR A COMPANY SALE, MERGER, BUSINESS COMBINATION, OR
OTHER TRANSACTIONS
    * SIO GENE THERAPIES INC - SVB SECURITIES WILL ACT AS SIO'S
FINANCIAL ADVISOR WITH RESPECT TO STRATEGIC REVIEW PROCESS
    * SIO GENE THERAPIES INC - COMPANY HAD CASH AND CASH
EQUIVALENTS
OF APPROXIMATELY $64 MILLION AT MARCH 31, 2022
    * SIO GENE THERAPIES INC - LICENSE TERMINATION AND RELATED
HEADCOUNT REDUCTION LOWERS OPERATING EXPENSES SIGNIFICANTLY

Source text for Eikon:  ID:nGNX1F0N9X 
Further company coverage:  SIOX.O